Royal Marsden phase III trial of fluorouracil with or without interferon alfa-2b in advanced colorectal cancer

Journal of Clinical Oncology

Volumn 13, Issue 6, 1995, Pages 1297-1302

  Hill, Mark ^a   Norman, Andrew ^a   Cunningham, David ^a,b   Findlay, Michael ^a   Nicolson, Viola ^a   Hill, Andrea ^a   Iveson, Angela ^a   Evans, Christopher ^a   Joffe, Jonathan ^a   Nicolson, Marianne ^a   Hickish, Tamas ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; FLUOROURACIL;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DOSE RESPONSE; DRUG MECHANISM; ERYTHEMA; FEMALE; FEVER; GASTROINTESTINAL TOXICITY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LETHARGY; LEUKOPENIA; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; PHASE 3 CLINICAL TRIAL; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME;

EID: 0029016021     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1995.13.6.1297     Document Type: Article

References (19)

1. Boring CC, Squires T, Tong T: Cancer statistics 1993. CA 43:7-26, 1993
2. Moertel CG, Fleming TR, MacDonald JS, et al: Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 322:352-8, 1990
3. Scheithauer W, Rosen H, Kornek G-V, et al: Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer. BMJ 306:752-755, 1993
4. The Nordic Gastrointestinal Tumour Adjuvant Therapy Group: Expectancy or primary chemotherapy in patients with advanced asymptomatic colorectal cancer: A randomized trial. J Clin Oncol 10:904-911, 1992
5. Elias L, Sandoval JM: Interferon effects upon flourouracil metabolism by HL-60 cells. Biochem Biophys Res Commun 163:867-874, 1989
6. Houghton JA, Morton C, Adkins D, et al: Locus of the interaction among 5-flourouracil, leucovorin and interferon-α2a in colon carcinoma cells. Cancer Res 53:4243-4250, 1993
7. Chu E, Zinn S, Boarman D, et al: Interaction of gamma interferon and 5-flourouracil in H630 human colon carcinoma cell line. Cancer Res 50:5834-5840, 1990
8. Pfeffer LM, Tamm I: Interferon inhibition of thymidine incorporation into DNA through effects on thymidine transport and uptake. J Cell Physiol 121:431-436, 1984
9. Danhauser LL, Freimann JH, Gilchrist TL, et al: Phase I and plasma pharmacokinetic study of infusional flourouracil combined with recombinant interferon alpha-2b in patients with advanced cancer. J Clin Oncol 11:751-761, 1993
10. Wadler S, Schwartz EL, Goldman M, et al: Flourouracil and recombinant alfa-2a-interferon: An active regimen against colorectal carcinoma. J Clin Oncol 7:1769-1775, 1989
11. Wadler S, Lembersky B, Atkins M, et al: Phase II trial of flourouracil and recombinant interferon alfa-2a in patients with advanced colorectal carcinoma: An Eastern Cooperative Oncology Group study. J Clin Oncol 9:1806-1810, 1991
12. Kemeny N, Younes A, Seiter K, et al: Interferon alpha-2A and 5-flourouracil for advanced colorectal carcinoma. Assessment of activity and toxicity. Cancer 66:2470-2475, 1990
13. Pazdur R, Ajani JA, Patt YZ, et al: Phase II study of flourouracil and recombinant interferon alfa-2a in previously untreated advanced colorectal carcinoma. J Clin Oncol 8:2027-2031, 1990
14. Miller AB, Hoogstraaten B, Staquet M, et al: Reporting results of cancer treatment. Cancer 47:207-214, 1981
15. Kaplan EL, Meier P: Non parametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
16. Peto R, Peto J: Asymtotically efficient invariant procedures. J R Stat Soc A 135:185-206, 1972
17. York M, Greco FA, Figlin RA, et al: A randomised phase III trial comparing 5-FU with or without interferon alfa 2a for advanced colorectal cancer. Proc Am Soc Clin Oncol 12:200, 1993 (abstr 590)
18. Seymour MT, Patel N, Johnston A, et al: Lack of effect of interferon α2a upon flourouracil pharmacokinetics. Br J Cancer 70:724-728, 1994
19. Findlay MP, Hill AS, Cunningham D, et al: Protracted venous infusion 5-flourouracil and interferon-α in advanced and refractory colorectal cancer. Ann Oncol 5:239-243, 1994